AIMS: We determined whether or not the extent of drug interaction of fexofenadine by itraconazole is time-dependent. METHODS: In a randomized two-phase crossover study, itraconazole was administered orally for 6 days, and, on days 1, 3 and 6, fexofenadine was administered simultaneously. On another occasion, fexofenadine was administered alone. RESULTS:Itraconazole increased fexofenadine AUC(0, infinity), and the % change for difference was 178% (95% CI 1235, 3379), 205% (95% CI 1539, 3319) and 169% (95% CI 1128, 2987) on days 1, 3 and 6 of the 6 day treatment, respectively. CONCLUSIONS: The extent of drug interaction by itraconazole was not time-dependent.
RCT Entities:
AIMS: We determined whether or not the extent of drug interaction of fexofenadine by itraconazole is time-dependent. METHODS: In a randomized two-phase crossover study, itraconazole was administered orally for 6 days, and, on days 1, 3 and 6, fexofenadine was administered simultaneously. On another occasion, fexofenadine was administered alone. RESULTS:Itraconazole increased fexofenadine AUC(0, infinity), and the % change for difference was 178% (95% CI 1235, 3379), 205% (95% CI 1539, 3319) and 169% (95% CI 1128, 2987) on days 1, 3 and 6 of the 6 day treatment, respectively. CONCLUSIONS: The extent of drug interaction by itraconazole was not time-dependent.
Authors: Mikko Niemi; Kari T Kivistö; Ute Hofmann; Matthias Schwab; Michel Eichelbaum; Martin F Fromm Journal: Br J Clin Pharmacol Date: 2005-05 Impact factor: 4.335
Authors: Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger Journal: Clin Pharmacokinet Date: 2010-04 Impact factor: 6.447
Authors: Stacy S Shord; Lingtak-Neander Chan; Joseph R Camp; Eva M Vasquez; Hyun-Young Jeong; Robert E Molokie; Charles L Baum; Hui Xie Journal: Br J Clin Pharmacol Date: 2010-02 Impact factor: 4.335